Corbus Pharmaceuticals Holdings, Inc. (CRBP): EBITDA
-$85.08M
Year ended 2025-12-31
-$106.68M
Trailing 12 months to 2026-06-30
| Period ended | EBITDA | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$85.08M | n/m | 2026-03-09, From 2025-01-01 |
| 2024-12-31 | -$48.13M | n/m | 2026-03-09, From 2024-01-01 |
| 2023-12-31 | -$44.44M | n/m | 2025-03-11, From 2023-01-01 |
| 2022-12-31 | -$39.07M | n/m | 2024-03-12, From 2022-01-01 |
| 2021-12-31 | -$54.99M | n/m | 2023-03-07, From 2021-01-01 |
| 2020-12-31 | -$121.69M | n/m | 2022-03-08, From 2020-01-01 |
| 2019-12-31 | -$76.37M | n/m | 2021-03-15, From 2019-01-01 |
| 2018-12-31 | -$56.25M | n/m | 2020-03-16, From 2018-01-01 |
| 2017-12-31 | -$32.31M | n/m | 2019-03-12, From 2017-01-01 |
| 2016-12-31 | -$19.90M | n/m | 2018-03-12, From 2016-01-01 |
| 2015-12-31 | -$8.81M | n/a | 2018-03-12, From 2015-01-01 |
EBITDA at similar companies
| Company | Year ended | EBITDA | Change YoY |
|---|---|---|---|
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | 2025-12-31 | -$85.08M | n/m |
| Climb Bio, Inc. (CLYM) | 2025-12-31 | -$67.79M | n/m |
| Gyre Therapeutics, Inc. (GYRE) | 2025-12-31 | $13.97M | -21.1% |
| Gossamer Bio, Inc. (GOSS) | 2025-12-31 | -$170.70M | n/m |
| PepGen Inc. (PEPG) | 2025-12-31 | -$92.21M | n/m |
| Transcode Therapeutics, Inc. (RNAZ) | 2025-12-31 | -$27.90M | n/m |
| Aclaris Therapeutics, Inc. (ACRS) | 2025-12-31 | -$75.92M | n/m |
| Aquestive Therapeutics, Inc. (AQST) | 2025-12-31 | -$70.50M | n/m |
| Boundless Bio, Inc. (BOLD) | 2025-12-31 | -$62.30M | n/m |
Compare CRBP, CLYM, GYRE, GOSS side by side · Screen every company in Pharmaceutical Preparations ↗